<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
    /* References section styling */
    .refs-section { border: 1px solid var(--border); border-radius: 12px; padding: 16px; background: var(--card); }
    .refs-title { font-size: 16px; font-weight: 700; color: #1f2937; margin: 0 0 16px 0; padding-bottom: 8px; border-bottom: 2px solid var(--accent); }
    .ref-category { margin-bottom: 16px; }
    .ref-cat-header { font-size: 14px; font-weight: 600; color: #374151; margin-bottom: 10px; padding: 6px 10px; background: linear-gradient(135deg, #f3f4f6 0%, #e5e7eb 100%); border-radius: 6px; }
    .ref-entry { margin-bottom: 10px; padding: 10px 12px; background: #fafafa; border-radius: 8px; border-left: 3px solid var(--accent); }
    .ref-tag { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, monospace; font-size: 12px; font-weight: 600; color: var(--accent); margin-bottom: 6px; word-break: break-all; }
    .ref-details { font-size: 13px; color: #4b5563; line-height: 1.6; }
    .ref-detail-line { margin-bottom: 2px; }
    /* Category-specific colors */
    .ref-guidelines .ref-entry { border-left-color: #059669; }
    .ref-guidelines .ref-tag { color: #059669; }
    .ref-literature .ref-entry { border-left-color: #7c3aed; }
    .ref-literature .ref-tag { color: #7c3aed; }
    .ref-clinical-trials .ref-entry { border-left-color: #dc2626; }
    .ref-clinical-trials .ref-tag { color: #dc2626; }
    .ref-clinical-reports .ref-entry { border-left-color: #d97706; }
    .ref-clinical-reports .ref-tag { color: #d97706; }
    /* Mermaid chart styling */
    .mermaid-container { border-color: #10b981; }
    .mermaid-container > summary { color: #059669; }
    .mermaid-chart { padding: 16px; background: linear-gradient(135deg, #f0fdf4 0%, #ecfdf5 100%); border-radius: 10px; margin-top: 10px; overflow-x: auto; }
    .mermaid-chart svg { max-width: 100%; height: auto; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class='card stats-card' style='background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%); border: 2px solid #0ea5e9; margin-bottom: 16px;'>
<h2 style='margin-top: 0; color: #0369a1;'>ğŸ“Š Pipeline Execution Statistics</h2>
<div style='margin-bottom: 12px;'>
<strong>â±ï¸ Total Execution Time:</strong> 1321.7 seconds (22åˆ†1ç§’)
</div>
<div style='margin-bottom: 12px;'>
<strong>ğŸ”¢ Total Tokens:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li>Input: 101,280</li>
<li>Output: 38,347</li>
<li>Total: 139,627</li>
</ul>
</div>
<div style='margin-bottom: 8px;'>
<strong>ğŸ¤– Models Used:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li style='margin-bottom: 6px;'>
<strong>deepseek/deepseek-r1 (Openrouter)</strong>: 
23 calls, 
139,627 tokens 
(101,280 in / 38,347 out)
</li>
</ul>
</div>
</div>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-21_07-45-34</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>**Final Assessment:**  
Recurrent platinum-resistant ovarian clear cell carcinoma (HNF1B+, HRD-negative) with progressive liver/bone metastases [@2022-12-29 | MR/CT]; ATM p.Y316C variant [@OH2203828 | Genomics] of uncertain significance. Key uncertainties: PDL1 status, ATM pathogenicity, and occult disease extent.  

**Core Treatment Strategy:**  
- Start **non-platinum chemotherapy (e.g., weekly paclitaxel)** immediately per NCCN platinum-resistant recurrence guidelines [@guideline:nccn_ovariancancer_v3_2025 | Page 22].  
- **Await PDL1 (CPS) results** from archival tissue to guide immunotherapy integration per ESMO recommendations [@guideline:esmo_cpg_epithelialovarian_2023 | Page 10].  
- Enroll in **BL-B01D1 clinical trial [@trial | 350]** if molecular review confirms eligibility post-PET/CT.  
- Convene molecular tumor board to assess ATM variant for PARPi trials despite HRD negativity [@OH2203828 | Genomics].  

**Change Triggers:**  
- If PDL1 â‰¥1% CPS, add **anti-PD1 (e.g., pembrolizumab)** to chemotherapy per ESMO [@guideline:esmo_cpg_epithelialovarian_2023 | Page 12].  
- If PET/CT reveals new occult lesions, escalate to **combination therapy Â± radiation for symptomatic sites** [@guideline:nccn_ovariancancer_v3_2025 | Page 18].  
- If ATM variant deemed pathogenic, prioritize **PARPi-inclusive trials** over standard chemo [@guideline:nccn_ovariancancer_v3_2025 | Page 14].  

---  
*Tags validated against MDT discussion and clinical reports.*</pre>
<div class='refs-section mt'>
<h3 class='refs-title'>References</h3>
<div class='ref-category ref-guidelines'>
<div class='ref-cat-header'>ğŸ“‹ Guidelines</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:nccn_ovariancancer_v3_2025 | Page 22]</div>
<div class='ref-details'>
<div class='ref-detail-line'>[Not cached]</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:esmo_cpg_epithelialovarian_2023 | Page 10]</div>
<div class='ref-details'>
<div class='ref-detail-line'>[Not cached]</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:esmo_cpg_epithelialovarian_2023 | Page 12]</div>
<div class='ref-details'>
<div class='ref-detail-line'>[Not cached]</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:nccn_ovariancancer_v3_2025 | Page 18]</div>
<div class='ref-details'>
<div class='ref-detail-line'>[Not cached]</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:nccn_ovariancancer_v3_2025 | Page 14]</div>
<div class='ref-details'>
<div class='ref-detail-line'>[Not cached]</div>
</div>
</div>
</div>
<div class='ref-category ref-literature'>
<div class='ref-cat-header'>ğŸ“š Literature</div>
</div>
<div class='ref-category ref-clinical-trials'>
<div class='ref-cat-header'>ğŸ”¬ Clinical Trials</div>
<div class='ref-entry'>
<div class='ref-tag'>[@trial | 350]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Trial ID: 350</div>
<div class='ref-detail-line'>Name: è¯„ä»·æ³¨å°„ç”¨BL-B01D1åœ¨å¤å‘æˆ–è½¬ç§»æ€§å¦‡ç§‘æ¶æ€§è‚¿ç˜¤ç­‰å¤šç§å®ä½“ç˜¤æ‚£è€…ä¸­çš„å®‰å…¨æ€§ã€è€å—æ€§ã€è¯ä»£åŠ¨åŠ›å­¦åŠæœ‰æ•ˆæ€§çš„Ib/IIæœŸä¸´åºŠç ”ç©¶</div>
<div class='ref-detail-line'>Rationale: Matches recurrent ovarian cancer (å¦‡ç§‘æ¶æ€§è‚¿ç˜¤) in 2L setting with no biomarker requirement.</div>
</div>
</div>
</div>
<div class='ref-category ref-clinical-reports'>
<div class='ref-cat-header'>ğŸ“„ Clinical Reports</div>
<div class='ref-entry'>
<div class='ref-tag'>[@OH2203828 | Genomics]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Genomics ID: OH2203828 | Date: 2022-04-18</div>
<div class='ref-detail-line'>Content: ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1...</div>
</div>
</div>
</div>
</div>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>åµå·¢æ¶æ€§è‚¿ç˜¤ï¼šåµå·¢ç™Œå¤å‘ï¼šæœ¯å‰CA125 45.7 CA199 161 HE4 562022.03.28åœ¨å…¨éº»ä¸‹è¡Œâ€œç˜¤ä½“å‡ç­æœ¯+ç›´è‚ ä¹™çŠ¶ç»“è‚ éƒ¨åˆ†åˆ‡é™¤æœ¯+é˜´é“éƒ¨åˆ†åˆ‡é™¤æœ¯+è…¹è†œåç—…æŸåˆ‡é™¤æœ¯+å¤æ‚è‚ ç²˜è¿æ¾è§£æœ¯+å·¦è¾“å°¿ç®¡æ”¯æ¶ç½®ç®¡æœ¯+è†€èƒ±ä¿®è¡¥æœ¯ã€‚ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œï¼Œç»“åˆT2022-04771é¦–å…ˆè€ƒè™‘ä¸ºé€æ˜ç»†èƒç™Œï¼Œæ­£åœ¨åŠ åšå…ç–«ç»„åŒ–è¿›ä¸€æ­¥æ˜ç¡®ã€‚è‚¿å—å¤§å°çº¦7*4*2.5cmã€‚åŒä¾§åˆ‡ç¼˜é˜´æ€§ï¼Œè‚ å‘¨æ·‹å·´ç»“ï¼ˆ4/15ï¼‰è§ç™Œè½¬ç§»ï¼Œä¼´ç™Œç»“èŠ‚1æšã€‚ï¼ˆè†€èƒ±åå£è‚¿ç˜¤ï¼‰çº¤ç»´è„‚è‚ªç»„ç»‡ï¼Œå±€ç¶çº¤ç»´ç»„ç»‡å¢ç”Ÿã€å«é“è¡€é»„ç´ æ²‰ç§¯ã€æ³¡æ²«æ ·ç»„ç»‡ååº”ï¼Œæœªè§ç™Œç´¯åŠã€‚è¡¥å……è¯Šæ–­1ï¼šã€è¡¥å……æŠ¥å‘Šã€‘ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰å¯ç¬¦åˆåµå·¢é€æ˜ç»†èƒç™Œç´¯åŠã€‚å…ç–«ç»„åŒ–ï¼ˆHI22-06789ï¼‰ç˜¤ç»†èƒï¼šMLH1(ES05)ï¼ˆ+ï¼‰ï¼ŒMSH6ï¼ˆ+ï¼‰ï¼ŒMSH2ï¼ˆ+ï¼‰ï¼ŒPMS2ï¼ˆ+ï¼‰ï¼ŒERï¼ˆéƒ¨åˆ†+ï¼‰ï¼ŒPRï¼ˆå°‘å¼±+ï¼‰ï¼ŒP53ï¼ˆ+/-ï¼‰ï¼ŒWT1ï¼ˆ-ï¼‰ï¼ŒKi-67ï¼ˆ60%+ï¼‰ï¼ŒHNF1Bï¼ˆ+ï¼‰ï¼ŒNapsinAï¼ˆç¶+ï¼‰ï¼ŒP16ï¼ˆ+ï¼‰ï¼ŒPAX8ï¼ˆ+ï¼‰ï¼ŒSALL4ï¼ˆ-ï¼‰ï¼ŒZBTB16ï¼ˆ-ï¼‰æœ¯åç™½ç´«+å¡é“‚åŒ–ç–—6ç¨‹ï¼Œæœ«æ¬¡ï¼š2022.8.172022.08.15ï¼šCA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/mlâ†‘,CEA:1.92ng/ml,HE4:87.90pmol/Lâ†‘,ROMA:23.55%(ç»ç»å‰)â†‘,ROMA.:18.89%(ç»ç»å)MRï¼ˆ2022.07.17ï¼‰ï¼š2022.08.15ï¼šCA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/mlâ†‘,CEA:1.92ng/ml,HE4:87.90pmol/Lâ†‘,ROMA:23.55%(ç»ç»å‰)â†‘,ROMA.:18.89%(ç»ç»å)è‚¿ç˜¤æ ‡å¿—ç‰©ï¼ˆ2022.10.12ï¼‰ï¼šCA19-9:77.20U/mlâ†‘,CA125:89.60U/mlâ†‘,AFP:&lt;0.91ng/ml,CEA:1.31ng/ml,HE4:59.70pmol/L,ROMA:12.07%(ç»ç»å‰)â†‘,ROMA.:36.67%(ç»ç»å)â†‘ã€‚CTï¼ˆ2022.10.25ï¼‰ï¼šè‚å†…å¤šå‘ç»“èŠ‚ï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ï¼Œè½¬ç§»å¯èƒ½ï¼Œè¯·ç»“åˆMRæ£€æŸ¥ã€‚å¦è§è‚å›Šè‚¿åŒå‰ã€‚MRï¼ˆ2022.10.24ï¼‰ï¼šç›†è…”æœ¯åï¼Œéª¶å‰å ä½ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»éª¶éª¨å—ç´¯å¯èƒ½ã€‚ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚2022.11.10å¤–é™¢è¡€å¸¸è§„ï¼šç™½ç»†èƒ 2.36ï¼Œçº¢ç»†èƒ 3.56ï¼Œè¡€çº¢è›‹ç™½ 97ï¼Œè¡€å°æ¿ 153å¤–é™¢ç”ŸåŒ–ï¼šALPã€€105ï¼ŒNA 136ï¼ŒPAB 1242022.11.30å¤–é™¢è¡€å¸¸è§„ï¼šç™½ç»†èƒ 3.46ï¼Œçº¢ç»†èƒ 3.48ï¼Œè¡€çº¢è›‹ç™½ 94ï¼Œè¡€å°æ¿ 1342022.11.17å¤–é™¢è‚¿ç˜¤æŒ‡æ ‡ï¼šCA125ã€€403ï¼ŒCa153ã€€63.8ï¼ŒCa199 96.8ï¼ŒCa724 695è‚¿ç˜¤æ ‡å¿—ç‰©ï¼ˆ2022.12.29ï¼‰ï¼šCA19-9:229.00U/mlâ†‘,CA125:933.00U/mlâ†‘,CA15-3:86.00U/mlâ†‘,CEA:1.49ng/ml,NSE:9.06ng/ml,HE4:111.00pmol/Lâ†‘,ROMA:41.02%(ç»ç»å‰)â†‘,ROMA.:85.98%(ç»ç»å)â†‘ã€‚MRï¼ˆ2022.12.30ï¼‰ï¼šç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚CTï¼ˆ2022.12.30ï¼‰ï¼šè‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚å¦è§è‚å›Šè‚¿åŒå‰ã€‚è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚å’¨è¯¢æŠ¥å‘Š</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;ç™½ç´«+å¡é“‚&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;&lt;0.91 ng/ml (2022-10-12)&quot;,&quot;CA125&quot;:&quot;933.00 U/ml (2022-12-29)&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;High-grade adenocarcinoma involving full-thickness intestinal wall&quot;,&quot;Lymph node metastasis (4/15)&quot;,&quot;Peritoneal/rectal/vaginal involvement described&quot;],&quot;histology&quot;:&quot;é€æ˜ç»†èƒç™Œ; è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œ&quot;,&quot;laterality&quot;:&quot;Unknown&quot;,&quot;primary&quot;:&quot;åµå·¢ç™Œå¤å‘&quot;,&quot;site&quot;:&quot;Ovary&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Unknown&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;6&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;intent&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;ç™½ç´«+å¡é“‚&quot;,&quot;start_date&quot;:&quot;Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;56&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;56&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;evidence&quot;:&quot;Rise in CA125/CA19-9 on 2022-10-12&quot;,&quot;evidence_type&quot;:&quot;Biochemical&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;Unknown&quot;,&quot;status&quot;:&quot;Resistant&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;56&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Resistant&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Resistant&quot;,&quot;RELAPSE&quot;:&quot;Yes&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;evidence&quot;:&quot;Elevated CA125 and CA19-9 on 2022-10-12; imaging (MRI 2022-10-24, CT 2022-10-25) supports recurrence&quot;,&quot;type&quot;:&quot;Biochemical&quot;},&quot;SCENE&quot;:&quot;Platinum_resistant_relapse&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Tumor debulking + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Surgical resection&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of ç™½ç´«+å¡é“‚ chemotherapy, last given 2022-08-17&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Post-chemo tumor markers reduced on 2022-08-15&quot;,&quot;regimen_or_test&quot;:&quot;ç™½ç´«+å¡é“‚&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Rising tumor markers indicating recurrence&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9 77.20 U/ml; CA125 89.60 U/ml&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Presacral lesion and pelvic mesenteric nodules, possible metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT shows multiple liver nodules, some new compared to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple hepatic metastatic nodules&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Markedly elevated tumor markers consistent with progression&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Progression of pelvic and hepatic metastatic disease&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis; CT abdomen&quot;}]},&quot;VISIT_DATE&quot;:&quot;2023-01-03&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;last_platinum_end_date&quot;:&quot;2022-08-17&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;14.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;89.60&quot;},{&quot;date&quot;:&quot;2022-11-17&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;403&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;933.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;933.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;CA19-9&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;7.16&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;77.20&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;229.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;229.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;HE4&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;87.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;59.70&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;111.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;111.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;pmol/L&quot;},{&quot;analyte&quot;:&quot;AFP&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Primary cytoreductive surgery performed&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of ç™½ç´«+å¡é“‚&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Biochemical relapse with rising tumor markers&quot;,&quot;type&quot;:&quot;Relapse&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;6 cycles of ç™½ç´«+å¡é“‚, last 2022-08-17&quot;,&quot;last_admin_date&quot;:&quot;2022-08-17&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;ç™½ç´«+å¡é“‚&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;Tumor size ~7x4x2.5 cm&quot;,&quot;Bilateral margins negative&quot;,&quot;Pericolic lymph nodes 4/15 positive&quot;,&quot;One tumor nodule (posterior bladder)&quot;],&quot;date&quot;:&quot;2022-03-28&quot;,&quot;diagnosis&quot;:&quot;Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma&quot;,&quot;grade&quot;:&quot;High-grade&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;MLH1&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;MSH6&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;MSH2&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;PMS2&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;partial+&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;few weak+&quot;},{&quot;marker&quot;:&quot;P53&quot;,&quot;result&quot;:&quot;+/-&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;60%+&quot;},{&quot;marker&quot;:&quot;HNF1B&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;NapsinA&quot;,&quot;result&quot;:&quot;focal+&quot;},{&quot;marker&quot;:&quot;P16&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;SALL4&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;ZBTB16&quot;,&quot;result&quot;:&quot;-&quot;}],&quot;involvement_sites&quot;:[&quot;Rectosigmoid colon&quot;,&quot;Left retroperitoneum&quot;,&quot;Vagina&quot;,&quot;Pericolic lymph nodes&quot;,&quot;Posterior bladder nodule&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;åµå·¢æ¶æ€§è‚¿ç˜¤ï¼šåµå·¢ç™Œå¤å‘ï¼šæœ¯å‰CA125 45.7 CA199 161 HE4 562 2022.03.28åœ¨å…¨éº»ä¸‹è¡Œâ€œç˜¤ä½“å‡ç­æœ¯+ç›´è‚ ä¹™çŠ¶ç»“è‚ éƒ¨åˆ†åˆ‡é™¤æœ¯+é˜´é“éƒ¨åˆ†åˆ‡é™¤æœ¯+è…¹è†œåç—…æŸåˆ‡é™¤æœ¯+å¤æ‚è‚ ç²˜è¿æ¾è§£æœ¯+å·¦è¾“å°¿ç®¡æ”¯æ¶ç½®ç®¡æœ¯+è†€èƒ±ä¿®è¡¥æœ¯ã€‚ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œï¼Œç»“åˆT2022-04771é¦–å…ˆè€ƒè™‘ä¸ºé€æ˜ç»†èƒç™Œï¼Œæ­£åœ¨åŠ åšå…ç–«ç»„åŒ–è¿›ä¸€æ­¥æ˜ç¡®ã€‚è‚¿å—å¤§å°çº¦7*4*2.5cmã€‚åŒä¾§åˆ‡ç¼˜é˜´æ€§ï¼Œè‚ å‘¨æ·‹å·´ç»“ï¼ˆ4/15ï¼‰è§ç™Œè½¬ç§»ï¼Œä¼´ç™Œç»“èŠ‚1æšã€‚ï¼ˆè†€èƒ±åå£è‚¿ç˜¤ï¼‰çº¤ç»´è„‚è‚ªç»„ç»‡ï¼Œå±€ç¶çº¤ç»´ç»„ç»‡å¢ç”Ÿã€å«é“è¡€é»„ç´ æ²‰ç§¯ã€æ³¡æ²«æ ·ç»„ç»‡ååº”ï¼Œæœªè§ç™Œç´¯åŠã€‚è¡¥å……è¯Šæ–­1ï¼šã€è¡¥å……æŠ¥å‘Šã€‘ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰å¯ç¬¦åˆåµå·¢é€æ˜ç»†èƒç™Œç´¯åŠã€‚å…ç–«ç»„åŒ–ï¼ˆHI22-06789ï¼‰ç˜¤ç»†èƒï¼šMLH1(ES05)ï¼ˆ+ï¼‰ï¼ŒMSH6ï¼ˆ+ï¼‰ï¼ŒMSH2ï¼ˆ+ï¼‰ï¼ŒPMS2ï¼ˆ+ï¼‰ï¼ŒERï¼ˆéƒ¨åˆ†+ï¼‰ï¼ŒPRï¼ˆå°‘å¼±+ï¼‰ï¼ŒP53ï¼ˆ+/-ï¼‰ï¼ŒWT1ï¼ˆ-ï¼‰ï¼ŒKi-67ï¼ˆ60%+ï¼‰ï¼ŒHNF1Bï¼ˆ+ï¼‰ï¼ŒNapsinAï¼ˆç¶+ï¼‰ï¼ŒP16ï¼ˆ+ï¼‰ï¼ŒPAX8ï¼ˆ+ï¼‰ï¼ŒSALL4ï¼ˆ-ï¼‰ï¼ŒZBTB16ï¼ˆ-ï¼‰&quot;,&quot;sample_type&quot;:&quot;Surgical resection&quot;,&quot;site&quot;:&quot;Partial rectosigmoid + left retroperitoneal tumor + partial vagina&quot;,&quot;tumor_size&quot;:&quot;7 x 4 x 2.5 cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;BRCA/HRD testing not reported&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Pelvis&quot;],&quot;date&quot;:&quot;2022-10-24&quot;,&quot;findings&quot;:[&quot;Postoperative pelvis with presacral mass; pelvic mesenteric multiple enhancing small nodules&quot;],&quot;impression&quot;:&quot;Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules likely metastases&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver&quot;],&quot;date&quot;:&quot;2022-10-25&quot;,&quot;findings&quot;:[&quot;Multiple intrahepatic nodules, some new compared to prior&quot;],&quot;impression&quot;:&quot;Probable metastases in liver&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;Pelvis; sacrum; right iliac bone&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Presacral lesion increased in size and heterogeneous enhancement; right iliac bone new enhancing nodule; pelvic mesenteric nodules similar&quot;],&quot;impression&quot;:&quot;Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver; spleen&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Multiple hepatic metastatic nodules increased in number and size; splenic patchy shadow suggesting possible infarct&quot;],&quot;impression&quot;:&quot;Progression of hepatic metastases&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Surgical resection&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of ç™½ç´«+å¡é“‚ chemotherapy, last given 2022-08-17&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Post-chemo tumor markers reduced on 2022-08-15&quot;,&quot;regimen_or_test&quot;:&quot;ç™½ç´«+å¡é“‚&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Rising tumor markers indicating recurrence&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9 77.20 U/ml; CA125 89.60 U/ml&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Presacral lesion and pelvic mesenteric nodules, possible metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT shows multiple liver nodules, some new compared to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple hepatic metastatic nodules&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Markedly elevated tumor markers consistent with progression&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Progression of pelvic and hepatic metastatic disease&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis; CT abdomen&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Clinical Trial Recommendation</summary>
    <pre>Trial Recommendation:
- id: 350
- name: è¯„ä»·æ³¨å°„ç”¨BL-B01D1åœ¨å¤å‘æˆ–è½¬ç§»æ€§å¦‡ç§‘æ¶æ€§è‚¿ç˜¤ç­‰å¤šç§å®ä½“ç˜¤æ‚£è€…ä¸­çš„å®‰å…¨æ€§ã€è€å—æ€§ã€è¯ä»£åŠ¨åŠ›å­¦åŠæœ‰æ•ˆæ€§çš„Ib/IIæœŸä¸´åºŠç ”ç©¶
- Reason: Matches recurrent ovarian cancer (å¦‡ç§‘æ¶æ€§è‚¿ç˜¤) in 2L setting with no biomarker requirement.
- Missing eligibility confirmations (0-2 items):
  - None</pre>
    <div class="hint">Shown only when the trial matcher produced a recommendation.</div>
  </details>

  <details class="mt" open>
    <summary>Expert Debate (Round Ã— Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Urgent PDL1 testing needed for immunotherapy eligibility in clear cell histology per ESMO guidelines [@guideline:esmo_cpg_epithelialovarian_2023 | Page 10]. PET/CT required for metabolic recurrence assessment as per NCCN recommendations [@guideline:nccn_ovariancancer_v3_2025 | Page 14].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>chair</td><td>PET/CT recommended per NCCN guidelines for comprehensive metabolic assessment of recurrence not available; critical given bone/visceral progression [@guideline:nccn_ovariancancer_v3_2025 | Page 18].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>chair</td><td>Urgently recommend PDL1 (CPS) testing per ESMO guidelines for clear cell carcinoma [@guideline:esmo_cpg_epithelialovarian_2023]. No PDL1 report exists [needs update].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>chair</td><td>PET/CT critically missing for metabolic staging of recurrence. NCCN recommends PET for occult disease detection in ovarian cancer [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18].</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;Based on current patient data and evidence:\n\n*   **RECURRENT PLATINUM-RESISTANT OCC:** Confirmed relapse with progressive metastases (liver, presacral/sacrum, iliac bone) within 56 days of last platinum [@2022-10-12 | CT/MR]; histology: clear cell carcinoma [@2022-03-28 | Pathology]. NCCN recommends non-platinum chemotherapy Â± targeted agents [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n*   **NGS FINDINGS:** ATM germline mutation (Y316C) detected [@OH2203828 | Genomics]; BRCA1/2, HRD, ARID1A negative [@OH2203828 | Genomics]. Clinical relevance of ATM variant in OCC unclear; impacts trial eligibility &amp; potential PARPi response.\n*   **NEED MOLECULAR REVIEW:** Urgent MDT discussion required for ATM variant interpretation (likely pathogenic) and biomarker-driven therapy options (trials/off-label). Confirm HRD/BRCA testing scope (tissue/germline). Update CA125 trend [@20221229|9703212 | LAB] since 12/29. Bone lesion assessment.&quot;,
  &quot;oncologist&quot;: &quot;Here is the initial oncology assessment:\n\n1.  Platinum-resistant relapse: PFI ~2 months since last platinum (2022-08-17), requiring non-platinum-based options or re-challenge strategies [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 14].\n2.  Biomarker gap: Missing PDL1 testing (CPS/TPS) crucial for immunotherapy consideration in clear cell histology [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]; needs urgent update. Genomic ATM variant [@OH2203828 | Genomics] (Y316C) clinical significance uncertain.\n3.  Organ function adequate: Labs show mild anemia (HGB 74 g/L [@20230103|5600862 | LAB]), normal creatinine (54 umol/L [@20230103|10100203 | LAB]), and normal LFTs. Supportive care needed.&quot;,
  &quot;radiologist&quot;: &quot;- Progressive presacral recurrence (53Ã—44mm) with sacral/iliac bone involvement and peritoneal nodules on 2022-12-29 MRI [@2022-12-29 | MR].  \n- New/worsening hepatic metastases (largest 17Ã—14mm) and possible splenic infarct on 2022-12-29 CT [@2022-12-29 | CT].  \n- Progressive disease on imaging requires systemic therapy reassessment per NCCN guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18].  &quot;,
  &quot;pathologist&quot;: &quot;Based on role-specific case view and molecular reports, with **&lt; 20 words per bullet** and **strict evidence tagging**:\n\n1.  Histology &amp; IHC support **ovarian clear cell carcinoma** recurrence (HNF1B+, NapsinA focal+, PAX8+, WT1-); however, **primary pathology report missing** [needs update].  \n2.  Comprehensive NGS confirms **HRD-negative**, **BRCA1/2 wild-type**, and **germline ATM p.Y316C** mutation [@OH2203828 | Genomics].  \n3.  NCCN classifies clear cell carcinoma as a distinct histotype with unique prognostic/therapeutic implications [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18].&quot;,
  &quot;nuclear&quot;: &quot;- No PET/CT available; metabolic assessment requires updated PET for recurrence evaluation.  \n- MRI/CT show progressive pelvic recurrence and hepatic metastases [@2022-12-29|MR] [@2022-12-29|CT], but metabolic patterns unknown without PET.  \n- NCCN guidelines recommend PET for detecting occult recurrence in ovarian cancer [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18].&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;**FINAL refined plan:**  \n*   **PDL1 testing initiation:** Pathologist to expedite PDL1 (CPS) testing on archival tissue for immunotherapy eligibility in clear cell carcinoma, per ESMO guidelines [@guideline:esmo_cpg_epithelialovarian_2023 | Page 10]. (Critical gap per pathologist/oncologist).  \n*   **PET/CT scheduling:** Nuclear medicine to schedule PET/CT within 48h for metabolic staging of recurrence (bone/visceral progression), mandated by NCCN [@guideline:nccn_ovariancancer_v3_2025 | Page 18]. (Critical gap per radiologist/nuclear).  \n*   **ATM variant adjudication:** Oncologist to convene molecular tumor board for ATM p.Y316C [@OH2203828 | Genomics] interpretation and PARPi trial eligibility, given HRD negativity. Update CA125 [@20221229|9703212 | LAB] trend pre-therapy.  \n\n---  \n*Tags align with reports/guidelines referenced in discussions.*&quot;,
    &quot;oncologist&quot;: &quot;1. Initiate non-platinum-based therapy for platinum-resistant recurrence per NCCN guidelines [@guideline:nccn_ovariancancer_v3_2025 | Page 14].  \n2. Expedite PDL1 testing (unknown) per ESMO recommendations [@guideline:esmo_cpg_epithelialovarian_2023 | Page 10] and PET/CT for metabolic assessment per NCCN [@guideline:nccn_ovariancancer_v3_2025 | Page 18].  \n3. Address anemia from blood count [@20230103|5600862 | LAB] and update CA125 trend [@20221229|9703212 | LAB needs update].&quot;,
    &quot;radiologist&quot;: &quot;- Urgent PET/CT required for metabolic recurrence assessment per NCCN guidelines given bone/visceral progression [@guideline:nccn_ovariancancer_v3_2025 | Page 18].  \n- Confirmed presacral recurrence progression (53Ã—44mm) with sacral/iliac involvement [@2022-12-29 | MR].  \n- Hepatic metastases progressed (largest 17Ã—14mm) with possible splenic infarct [@2022-12-29 | CT].&quot;,
    &quot;pathologist&quot;: &quot;1.  **Urgent PDL1 (CPS) testing required** for potential immunotherapy in clear cell histology per ESMO guidelines; no report exists [needs update] [@guideline:esmo_cpg_epithelialovarian_2023 | Page 10].  \n2.  **Original pathology report still missing**; critical for definitive histologic confirmation and baseline comparison [needs update].  \n3.  **Germline ATM p.Y316C variant detected** [@OH2203828 | Genomics]; NCCN notes ATM may influence PARPi eligibility despite HRD-negative status [@guideline:nccn_ovariancancer_v3_2025 | Page 18].&quot;,
    &quot;nuclear&quot;: &quot;- Urgent PET/CT required for metabolic recurrence assessment per NCCN guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18].  \n- PDL1 (CPS) testing critical for immunotherapy eligibility in clear cell histology [@guideline:esmo_cpg_epithelialovarian_2023 | Page 10].  \n- Confirm ATM p.Y316C variant pathogenicity via germline report [@OH2203828 | Genomics].&quot;
  }
}</pre>
  </details>

  <details class="mt" open>
    <summary>Selected Clinical Context</summary>
    <table class='grid'><tr><th>Role</th><th>Lab (n)</th><th>Lab newest</th><th>Imaging (n)</th><th>Imaging newest</th><th>Pathology (n)</th><th>Pathology newest</th><th>Mutation (n)</th><th>Mutation newest</th></tr><tr><td class='mono'>chair</td><td>3</td><td>2023-01-03</td><td>2</td><td>2022-12-29</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>nuclear</td><td>0</td><td>-</td><td>2</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr><tr><td class='mono'>oncologist</td><td>3</td><td>2023-01-03</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>pathologist</td><td>0</td><td>-</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>radiologist</td><td>0</td><td>-</td><td>2</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr></table>
    <div class="hint">Counts and newest dates per role/report type (including mutation).</div>
    <details class="mt">
      <summary>Raw Context (JSON)</summary>
      <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç¥ç»å…ƒç‰¹å¼‚çƒ¯é†‡åŒ–é…¶ 9.06 ng/ml (NSE)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 85.98 %(ç»ç»å) (ROMA.)\nç³–é“¾æŠ—åŸ15-3 86.00 U/ml (CA15-3)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 41.02 %(ç»ç»å‰) (ROMA)\näººé™„ç¾è›‹ç™½4 111.00 pmol/L (HE4)\nç™ŒèƒšæŠ—åŸ 1.49 ng/ml (CEA)\nç³–é“¾æŠ—åŸ125 933.00 U/ml (CA125)\nç³–é“¾æŠ—åŸ19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|10100203&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;æ€»èƒ†çº¢ç´  8.1 umol/l (TBIL)\nè°·æ°¨é…¸è„±æ°¢é…¶ 3.2 U/L (GLDH)\nÎ³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 34 U/L (GGT)\nå°¿ç´  4.24 mmol/l (UREA)\nç™½è›‹ç™½ 39.1 g/l (ALB)\næ€»è›‹ç™½ 70.4 g/l (TP)\nè°·è‰åŒå·¥é…¶ 7.3 U/L (ASTM)\nçƒè›‹ç™½ 31.3 g/l (GELO)\nå¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 26.5 U/L (AST)\nå°¿é…¸ 190 umol/l (UA)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.17 mmol/L (NEFA)\nç¢±æ€§ç£·é…¸é…¶ 109.4 U/L (ALP)\nå‰ç™½è›‹ç™½ 106 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  4.0 umol/L (IBIL)\nç›´æ¥èƒ†çº¢ç´  4.1 umol/l (DBIL)\nä¹³é…¸è„±æ°¢é…¶ 258 U/L (LDH)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 23.1 U/l (ALT)\nè‚Œé… 54 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.25 nan (A/G)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 76.5 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 12 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.01 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 0.20 % (BASO)\næ·‹å·´ç»†èƒæ•° 0.5 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 4.8 *10^9/L (GRAN#)\nçº¢ç»†èƒè®¡æ•° 2.84 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 259 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 18.6 % (RDWCV)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 305.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.28 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 57 nan (RDWSD)\nå•æ ¸ç»†èƒæ•° 0.9 *10^9/L (MID#)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— UNACCEPT nan (VFLAG)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 85.6 fl (MCV)\nç™½ç»†èƒè®¡æ•° 6.2 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 74 g/l (HGB)\nå—œé…¸æ€§ç»†èƒæ•° 0.00 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.00 % (EOS)\næ·‹å·´ç»†èƒ% 8.5 % (LYM)\nå•æ ¸ç»†èƒ% 14.8 % (MID)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 26.1 pg (MCH)\nçº¢ç»†èƒæ¯”ç§¯ 24.3 % (HCT)\nå¹³å‡PLTå®¹ç§¯ 10.9 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 9.60 nan (NL)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç¥ç»å…ƒç‰¹å¼‚çƒ¯é†‡åŒ–é…¶ 9.06 ng/ml (NSE)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 85.98 %(ç»ç»å) (ROMA.)\nç³–é“¾æŠ—åŸ15-3 86.00 U/ml (CA15-3)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 41.02 %(ç»ç»å‰) (ROMA)\näººé™„ç¾è›‹ç™½4 111.00 pmol/L (HE4)\nç™ŒèƒšæŠ—åŸ 1.49 ng/ml (CEA)\nç³–é“¾æŠ—åŸ125 933.00 U/ml (CA125)\nç³–é“¾æŠ—åŸ19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|10100203&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;æ€»èƒ†çº¢ç´  8.1 umol/l (TBIL)\nè°·æ°¨é…¸è„±æ°¢é…¶ 3.2 U/L (GLDH)\nÎ³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 34 U/L (GGT)\nå°¿ç´  4.24 mmol/l (UREA)\nç™½è›‹ç™½ 39.1 g/l (ALB)\næ€»è›‹ç™½ 70.4 g/l (TP)\nè°·è‰åŒå·¥é…¶ 7.3 U/L (ASTM)\nçƒè›‹ç™½ 31.3 g/l (GELO)\nå¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 26.5 U/L (AST)\nå°¿é…¸ 190 umol/l (UA)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.17 mmol/L (NEFA)\nç¢±æ€§ç£·é…¸é…¶ 109.4 U/L (ALP)\nå‰ç™½è›‹ç™½ 106 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  4.0 umol/L (IBIL)\nç›´æ¥èƒ†çº¢ç´  4.1 umol/l (DBIL)\nä¹³é…¸è„±æ°¢é…¶ 258 U/L (LDH)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 23.1 U/l (ALT)\nè‚Œé… 54 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.25 nan (A/G)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 76.5 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 12 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.01 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 0.20 % (BASO)\næ·‹å·´ç»†èƒæ•° 0.5 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 4.8 *10^9/L (GRAN#)\nçº¢ç»†èƒè®¡æ•° 2.84 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 259 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 18.6 % (RDWCV)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 305.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.28 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 57 nan (RDWSD)\nå•æ ¸ç»†èƒæ•° 0.9 *10^9/L (MID#)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— UNACCEPT nan (VFLAG)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 85.6 fl (MCV)\nç™½ç»†èƒè®¡æ•° 6.2 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 74 g/l (HGB)\nå—œé…¸æ€§ç»†èƒæ•° 0.00 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.00 % (EOS)\næ·‹å·´ç»†èƒ% 8.5 % (LYM)\nå•æ ¸ç»†èƒ% 14.8 % (MID)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 26.1 pg (MCH)\nçº¢ç»†èƒæ¯”ç§¯ 24.3 % (HCT)\nå¹³å‡PLTå®¹ç§¯ 10.9 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 9.60 nan (NL)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸å‡ï¼Œç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯ï¼Œå³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚ å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾è„ç‰‡çŠ¶ä½å¯†åº¦å½±ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚ è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚&quot;
      }
    ],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸å‡ï¼Œç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯ï¼Œå³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚ å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾è„ç‰‡çŠ¶ä½å¯†åº¦å½±ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚ è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚&quot;
      }
    ],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸å‡ï¼Œç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯ï¼Œå³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚ å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾è„ç‰‡çŠ¶ä½å¯†åº¦å½±ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚ è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚&quot;
      }
    ]
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;nuclear&quot;: []
  }
}</pre>
    </details>
  </details>

  <details class="mt">
    <summary>Guideline + PubMed RAG</summary>
    <h3>RAG Query</h3>
    <pre>Recurrent platinum-resistant ovarian clear cell carcinoma (HNF1B+/NapsinA+), MMR proficient, HRD-negative, BRCA-negative, germline ATM pathogenic variant (p.Y316C); metastases to liver, pelvis, and possible bone; histology: clear cell carcinoma</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre># GUIDELINE RAG
RAG Evidence Pack (top=5):
[1] score=0.6362 nccn_ovariancancer_v3_2025__v00000000 [PAGE 18] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18]
    Version 3.2025, 07/16/25 Â© 2025 National Comprehensive Cancer NetworkÂ® (NCCNÂ®), All rights reserved. NCCN GuidelinesÂ® and this illustration may not be reproduced in any form without the express written permission of NCCN. Note: All recommendations are category 2A unless otherwise indicated. NCCN Guiâ€¦
[2] score=0.6245 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 10] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]
    with ï¬rst line. This can probably be explained by an accu- mulative exposure to platinum.85 Several factors need to be taken into consideration for the selection of PARPis or anti-VEGF therapies in relapse including histotype, BRCA1/2-mut status, prior therapies (PARPi and/or bevacizumab), expected â€¦
[3] score=0.6240 nccn_ovariancancer_v3_2025__v00000000 [PAGE 22] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]
    Survivorship) Recurrent diseaset Hormonal therapyu or Chemotherapy (if not previously used), see OV-C (6 of 12) or Systemic therapyf,v â€¢ For platinum-sensitive disease, see OV-C (8 of 12) â€¢ For platinum-resistant disease, see OV-C (9 of 12) or Observation f See Principles of Systemic Therapy (OV-C) â€¦
[4] score=0.6240 esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 [PAGE 17] [@guideline:esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 | Page 17]
    17 Table 1 Indications for in vivo ovarian tissue preservation in ovarian neoplasms according to the histological type and the stage of the disease STAGE EPITHELIAL OVARIAN NEOPLASMS NON-EPITHELIAL OVARIAN NEOPLASMS BOT1 LGSC LGEC MCexp CCC HGSC HGEC MCinf GCT2 SCC GrCT SLCT3 SLCT4 IA IB IC1 IC2 ## â€¦
[5] score=0.6225 nccn_ovariancancer_v3_2025__v00000000 [PAGE 14] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 14]
    ff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of disease; clinical judgment and flexibility should be utilized in determining treatment options. gg Data are limited on primary and maintenance therapy for recurrent/ persistent LCOC. hh During and after treatâ€¦

# PUBMED RAG
(PUBMED: retrieval failed: 500 Server Error: Internal Server Error for url: http://495ga8uy7084.vicp.fun:17088/api/search-paper)</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6361947655677795,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 18,
    &quot;text&quot;: &quot;Version 3.2025, 07/16/25 Â© 2025 National Comprehensive Cancer NetworkÂ® (NCCNÂ®), All rights reserved. NCCN GuidelinesÂ® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nClear Cell Carcinoma of the Ovary\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nClear cell carcinoma\nof the ovaryg,h,i\nStage\nIC2â€“ IC3\nStage IA\nIB, IC1\nStage IIâ€“IV\nIV platinum-based therapy\n(see primary regimens for stage I disease\n[OV-C, 5 of 12])\nIV platinum-based therapy\n(see primary regimens for stage I disease\n[OV-C, 5 of 12])\nor\nObserveg\nSystemic therapy\n(OV-C, 6 of 12)\nLCOC-3\nPATHOLOGIC\nDIAGNOSISa\nADJUVANT TREATMENTf\nMONITORING/\nFOLLOW-UP\nMonitoring/Follow-up\n(including tumor testing)\nand\nRecurrence therapyj\n(OV-6)\nIf known BRCA1/2\nmutation, consider\nmaintenance therapy\n(post-primary therapy)\n(OV-5)\na WHO Histologic Classification (OV-E).\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ng If not previously done, consider surgical staging and resection of residual disease (OV-3).&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6245022416114807,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 10,
    &quot;text&quot;: &quot;with ï¬rst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for\nthe selection of PARPis or anti-VEGF therapies in relapse\nincluding histotype, BRCA1/2-mut status, prior therapies\n(PARPi and/or bevacizumab), expected response to plat-\ninum ChT, presence of symptoms (speciï¬cally ascites),\npersistent toxicities from prior therapies, no contraindica-\ntion to bevacizumab and patient preference. Generally, for\nsymptomatic patients requiring a rapid treatment response,\nthe combination of carboplatin with bevacizumab would be\nrecommended (Figure 3).\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nSystemic therapy when platinum is not an option\nFor some patients with recurrent ovarian cancer, platinum\nrechallenge may not be considered clinically appropriate.\nFor these patients, alternative systemic treatments are\navailable. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6240465044975281,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 22,
    &quot;text&quot;: &quot;Survivorship)\nRecurrent\ndiseaset\nHormonal therapyu\nor\nChemotherapy (if not previously used), see OV-C (6 of 12)\nor\nSystemic therapyf,v\nâ€¢ For platinum-sensitive disease, see OV-C (8 of 12)\nâ€¢ For platinum-resistant disease, see OV-C (9 of 12)\nor\nObservation\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions\n(OV-D).\no Validated molecular testing should be performed in a CLIA-approved facility\nusing the most recent available tumor tissue. Tumor molecular analysis is\nrecommended to include, at a minimum, tests to identify potential benefit from\ntargeted therapeutics that have tumor-specific or tumor-agnostic benefit including,\nbut not limited to, HER2 status (by IHC), BRCA1/2, HRD status, MSI, MMR,\nTMB, BRAF, FRÎ± (FOLR1), RET, and NTRK if prior testing did not include these\nmarkers. More comprehensive testing may be particularly important in LCOC with\nlimited approved therapeutic options (OV-B).\np CT is performed with oral and iodinated IV contrast (unless contraindicated due\nto anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI\nis performed with gadolinium-based contrast agents (unless contraindicated due&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6240218281745911,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000&quot;,
    &quot;page&quot;: 17,
    &quot;text&quot;: &quot;17\nTable 1\nIndications for in vivo ovarian tissue preservation in ovarian\nneoplasms according to the histological type and the stage\nof the disease\nSTAGE\nEPITHELIAL OVARIAN NEOPLASMS\nNON-EPITHELIAL OVARIAN NEOPLASMS\nBOT1\nLGSC\nLGEC\nMCexp\nCCC\nHGSC\nHGEC\nMCinf\nGCT2\nSCC\nGrCT\nSLCT3\nSLCT4\nIA\nIB\nIC1\nIC2\n##\nIC3\n##\nII-IV\n#\n\nfavourable oncologic selection criteria for fertility-sparing management as defined in\nthe text (based on the favourable survival and/or recurrence rates observed in cohorts and/\nor comparative studies (radical versus conservative) of patients treated with such characteris-\ntics).\n\noncologic selection criteria acceptable in selected cases (insufficient or conflicting data\nto evaluate accurately the results of the ovarian preservation in this subgroup of patients).\n\nunfavourable oncologic selection criteria for ovarian preservation (poorest survival\nobserved in patients having an ovarian preservation in these subgroups. It could be related\nto the use of ovarian preservation itself and/or the natural history of the disease (whatever\nthe preservation or not of the ovary) in these patients having poorest prognostic factors).&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6224738955497742,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 14,
    &quot;text&quot;: &quot;ff Definitions of platinum-sensitive and platinum-resistant disease\nrepresent a spectrum of disease; clinical judgment and flexibility should\nbe utilized in determining treatment options.\ngg Data are limited on primary and maintenance therapy for recurrent/\npersistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated\nas indicated with tumor markers and repeat imaging (with modalities\npreviously used) to document response and/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\njj Patients who do not respond and progress on two consecutive regimens\nwithout evidence of clinical benefits have diminished likelihood of\nbenefitting from additional therapy (Griffiths RW, et al. Int J Gynecol\nCancer 2011;21:58-65). Decisions to offer clinical trials, supportive care,\nor additional therapy should be made on an individual basis.\nkk Localized radiation therapy (RT) can be considered to palliate\nsymptoms and/or for oligometastatic disease.\nOV-8\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.&quot;
  }
]</pre>
    <h3>Evidence Digest (1:1 per RAG result)</h3>
    <pre>Here are 5 evidence bullets for MDT decision-making based solely on the provided RAG results:

- [1] NCCN ovarian cancer guidelines (v3.2025) designate all recommendations as Category 2A evidence unless otherwise specified [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18].  
- [2] Selection of PARP inhibitors or anti-VEGF therapies in relapsed epithelial ovarian cancer requires consideration of histotype, BRCA mutation status, prior PARPi/bevacizumab use, and expected treatment response [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10].  
- [3] For recurrent ovarian cancer, NCCN guidelines stratify systemic therapy options by platinum sensitivity (platinum-sensitive vs. platinum-resistant disease) and include hormonal therapy or chemotherapy as alternatives [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].  
- [4] Indications for ovarian tissue preservation in ovarian neoplasms are defined by histologic type and disease stage in ESGO/ESHRE/ESGE fertility-sparing guidelines [@guideline:esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 | Page 17].  
- [5] Platinum-sensitive and platinum-resistant disease represent a clinical spectrum; treatment decisions should utilize clinical judgment and acknowledge limited data for recurrent LCOC therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 14].</pre>
  </details>

  <details class='mt mermaid-container' open><summary>Pipeline Flow</summary><div class='mermaid-chart'>flowchart TD
  A[Load Case + Fingerprint] --> B[Load Reports]
  B --> C[Report Selection per Role]
  C --> D[Guideline+PubMed RAG]
  D --> E[Init Specialist Agents]
  E --> F[MDT Discussion Engine]
  F --> G[Trial Matching]
  G --> H[Final Chair Output]
  H --> I[Save Logs]</div></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-21T07:23:33.133533&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2023-01-03 08:53:29.260000&quot;,
      &quot;meta_info&quot;: &quot;340123197709263626&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:23:33.133890&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;2a31f255c155&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:23:33.397489&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 92,
      &quot;img_n&quot;: 10,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 1,
      &quot;cutoff_dt&quot;: &quot;2023-01-04 08:53:29&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:27:39.239281&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|10100203|2023-01-03&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|10100203|2023-01-03&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: [
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ]
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:27:39.246815&quot;,
    &quot;event&quot;: &quot;rag_key_facts&quot;,
    &quot;payload&quot;: {
      &quot;facts&quot;: &quot;DIAGNOSIS: primary=åµå·¢ç™Œå¤å‘; histology=é€æ˜ç»†èƒç™Œ; è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œ; components=High-grade adenocarcinoma involving full-thickness intestinal wall;Lymph node metastasis (4/15);Peritoneal/rectal/vaginal involvement described\nPATHOLOGY: Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma\nPLATINUM: status=Resistant; pfi_days=56\nBIOMARKERS: CA125=933.00 U/ml (2022-12-29); AFP=&lt;0.91 ng/ml (2022-10-12); TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2203828; date=2022-04-18; full_text=ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:28:01.627996&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;Recurrent platinum-resistant ovarian clear cell carcinoma (HNF1B+/NapsinA+), MMR proficient, HRD-negative, BRCA-negative, germline ATM pathogenic variant (p.Y316C); metastases to liver, pelvis, and possible bone; histology: clear cell carcinoma&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:28:01.628014&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;guideline&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:28:01.628017&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;pubmed&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 0
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:28:01.628019&quot;,
    &quot;event&quot;: &quot;rag_hits_merged&quot;,
    &quot;payload&quot;: {
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:28:28.787893&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:28:28.788088&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;order&quot;: 1
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:28:54.898558&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;chars&quot;: 953
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:28:54.898625&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;order&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:29:20.512373&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;chars&quot;: 724
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:29:20.512456&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;order&quot;: 3
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:29:33.457448&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;chars&quot;: 419
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:29:33.457517&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;order&quot;: 4
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:33:15.876348&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;chars&quot;: 607
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:33:15.876485&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;order&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:35:05.414278&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;chars&quot;: 385
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:39:39.788404&quot;,
    &quot;event&quot;: &quot;evidence_tag_warning&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist-&gt;chair/turn_1&quot;,
      &quot;preview&quot;: &quot;Urgently recommend PDL1 (CPS) testing per ESMO guidelines for clear cell carcinoma [@guideline:esmo_cpg_epithelialovarian_2023]. No PDL1 report exists [needs upâ€¦&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:44:13.218482&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 2391
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:44:13.220110&quot;,
    &quot;event&quot;: &quot;trial_matching_start&quot;,
    &quot;payload&quot;: {
      &quot;trials_json_path&quot;: &quot;files/all_trials_filtered.json&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:45:00.809465&quot;,
    &quot;event&quot;: &quot;trial_matching_end&quot;,
    &quot;payload&quot;: {
      &quot;recommended&quot;: false
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:45:00.809499&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T07:45:34.869424&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 2250
    }
  }
]</pre>
  </details>

  <!-- Mermaid.js for flowchart rendering -->
  <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      mermaid.initialize({
        startOnLoad: true,
        theme: 'default',
        flowchart: {
          useMaxWidth: true,
          htmlLabels: true,
          curve: 'basis'
        },
        securityLevel: 'loose'
      });
      // Re-render mermaid charts in .mermaid-chart containers
      document.querySelectorAll('.mermaid-chart').forEach(function(el) {
        el.classList.add('mermaid');
      });
      mermaid.init(undefined, '.mermaid-chart');
    });
  </script>
</body>
</html>
